ESI Group and the DesCartes Program Aiming at Transforming Singapore Into a Hybrid, Ethical and Sustainable Smart Nation
25.1.2022 10:00:00 EET | Business Wire | Press release
Regulatory News:
ESI Group, Rungis, France, (ISIN Code: FR0004110310, Mnemo: ESI), a global player in virtual prototyping for industries, is collaborating in the launch of the DesCartes project in Singapore by providing its scientists, its expertise in hybridization methods and its virtual prototyping software solutions to the various stakeholders.
DesCartes a 5-year and a 35 million euros budget collaborative program, has been selected by the National Research Foundation (NRF) of Singapore and is based on the CREATE campus, "Campus for research excellence and technological enterprise", the international research hub of Singapore. Behind this very French name lies one of the largest collaborative programs of the CNRS: the "Program on Intelligent Modelling for Decision-making in Critical Urban Systems", dedicated to Hybrid Artificial Intelligence.
A smart city project to a better extent: A smart nation project
For many years, many smart cities projects have been launched. The principle of these smart cities is to collect data generated by sensors, to deploy specific applications, such as sensors indicating air pollution, alerts on accidents, traffic conditions in real time... However, the concept of smart nation carried by Singapore differs from the others because it pushes the concept to its paroxysm: from the digitization of an entity, a building, a single system to the digitization of a whole city interacting in real time.
From electrical grid optimization to delivery drones
DesCartes is developing hybrid AI methods, combining AI with knowledge-based models (physics, engineering), to enable trusted, real-time decision-making that is "people-centric" and "in harmony with society." All in response to complex situations related to critical urban systems in the context of Singapore's "Smart Nation." This research will be applied, for example, to urban mobility or energy management, or to anticipate the needs of future transportation networks, smart industries, or smart buildings. "For example, we aim to develop solutions to optimize the supply and demand of the electricity network, or solutions to improve the flow of cab drones or delivery drones, or to develop intelligent predictive maintenance applied to industrial tools," explains Dominique Baillargeat, director of CNRS@CREATE. Systems in the city that will be able to analyze data on the use of services by the population and then make optimization decisions.
ESI's role in this project.
ESI, recognized worldwide for its predictive physics modeling and virtual prototyping expertise, will play several roles in this program. First, its Scientific Director, also a member of CNRS and ENSAM, Prof. Francisco Chinesta, will be the program director. In addition, the Group will make its performance simulation solutions (VPS, VA One, Simulation X, etc.) and its expertise in hybridization and model reduction methods available to the partners and the program. ESI will thus be able to predict material behavior in real time, anticipate incidents (associated with damage, cracks, corrosion, etc.), model the wind for better use of drones, and make city management more intelligent and human-friendly. Finally, ESI will bring all its engineering expertise to optimize the platform in which the data will be used to make the right decision at the right time.
Dr. Francisco Chinesta, leader of the engineering activity for ESI in this project, says: "The goal of the Singapore program is to think and design an interconnected smart city with features that will revolutionize the concept of smart cities. In this project, it is essential to place the citizen - the human, but also more generally the living - at the heart of the hybridization devices. All the partners in this project aim to make Singapore an ethical, responsible and secure new city."
The Descartes program partners
The Descartes project involves on the French side:
- CNRS
- 13 universities and prestigious schools : Université Paris-Saclay, Université Toulouse Paul Sabatier, Université Lyon III Jean Moulin, Université de Bordeaux, École Nationale de l'Aviation Civile, Université Paris Sciences & Lettres, Université de Strasbourg, Arts et Métiers, INP Grenoble, INP ENSEEIHT, Ecole Normale Supérieure de Paris-Saclay, Université Grenoble-Alpes, Université Côte-d'Azur.
and, on the Singaporean side:
- 3 universities: Nanyang Technology University, National University of Singapore, Singapore University of Technology and Design.
- A*STAR: Agency for Science, Technology and Research. A*STAR is the national R&D agency of Singapore.
It is developed in collaboration with five industrial partners: ARIA, CETIM MATCOR, EDF, ESI Group and Thales.
About ESI Group
Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation. Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high level specialists around the world and reported 2020 sales of €132.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com.
Follow ESI: LinkedIn | Facebook | Twitter | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005770/en/
Contact information
ESI - Press & Shareholders
Florence Barré
investors@esi-group.com
+33 1 49 78 28 28
Verbatee – Press & Investors Relations
Jérôme Goaer, j.goaer@verbatee.com, +33 6 61 61 79 34
Aline Besselièvre, a.besselievre@verbatee.com, +33 6 61 85 10 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom